MINC-trastuzumab (STM-001) / Suntec Medical - LARVOL DELTA

Selection of the optimal long-acting injectable formulation of ivermectin for use in humans to target malaria vectors in Western Africa: evaluation of pharmacokinetics and mosquitocidal efficacy in cattle under laboratory conditions. (PubMed, Parasit Vectors) - "The mdc-STM-001 formulation was identified as the optimal candidate for future use in humans. A single injection induced sustained mosquitocidal efficacy for at least 2 months, achieving HR > 4 against both susceptible and resistant Anopheles populations and meeting WHO PPC for malaria endectocides. Although extrapolation from cattle to humans requires caution, the favorable PK profile and robust entomological outcomes support progression to phase 1 clinical trials. Ivermectin's established safety record further strengthens the rationale for clinical development."

Journal • PK/PD data • Infectious Disease • Malaria

Correlation of Trop2 expression with in vivo sensitivity to sacituzumab govitecan in a panel of breast XPDX models (SABCS 2022) - "In vivo, 20% of ER+/Trop2+ models reported sensitivity to SG, most notably models from patients with acquired resistance to CDK4/6 inhibitors, including STM001 and ST4316B. We screened 180 models in our XPDX breast cancer platform for Trop2 expression and compared expression with in vivo SG efficacy in 125 models. Analysis is underway to correlate receptor and molecular profiles with SG sensitivity in breast models and we are expanding expression and in vivo testing to additional indications."

Preclinical • Breast Cancer • HER2 Breast Cancer • Oncology • Triple Negative Breast Cancer • ER • HER-2 • PGR • TACSTD2